Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Galenea
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Galenea is a privately held CNS-focused biotech using a proprietary synaptic transmission discovery platform (including the MANTRA system) to discover and advance preclinical small-molecule drugs for schizophrenia and other CNS disorders; no clinical-stage assets are publicly reported.[1][3][4]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Otsuka Pharmaceutical (research collaboration in schizophrenia and other CNS disorders)
Beyond the preview
Go deeper on Galenea.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galenea.